Pharmaxis Investor R&D Showcase Webinars

18th Mar 22

Release Date: 18/03/2022 9:37am

Clinicians to Speak About Pharmaxis Programs

Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) will host R&D showcase webinars for each of the Company’s two lead drug discoveries. Presentations by globally renowned clinicians and scientists involved in the Company’s clinical programs will be followed by Q&A sessions spearheaded by selected panels of biotech analysts and fund managers.

Pharmaxis drug PXS-5505 targeting several cancers:

Date & time: 29 March 2022 at 11.00am (AEDT)


  • Myelofibrosis - Dr Gabriela Hobbs, Assistant Professor, Medicine, Harvard Medical School & Clinical Director, Leukaemia, Massachusetts General Hospital
  • Hepatocellular carcinoma - Dr Paul Burchard, University of Rochester
  • Pancreatic cancer - Dr Tom Cox, A/Prof School of Clinical Medicine, UNSW Sydney, Laboratory Head - Matrix and Metastasis, Garvan Institute of Medical Research

To register for this event please use the following link:

 Pharmaxis drug PXS-6302 targeting scarring:

Date & time: 31 March 2022 at 11.00am (AEDT)


  • The science of scarring and potential for LOX inhibition - Dr. Mark Fear, Senior Research Fellow University of Western Australia
  • Clinical applications for LOX inhibition, unmet need and clinical development strategy - Professor Fiona Wood AM, Director of the Burn Injury Research Unit University of Western Australia

To register for this event please use the following link:

 The webinars are free to attend and a recording of the events will be made available on the Pharmaxis website. 

Read full media release - pdf

Categories: News and Media